American Society of Dermatopathology

View all recommendations from this society

October 17, 2018

Do not routinely perform the EWSR1 fluorescence in situ hybridization (FISH) assay on cases of clear cell sarcoma in situations where the translocation has been already detected by another testing modality.

Various testing modalities can be used to detect the translocation involving EWSR1 gene in clear cell sarcoma, with each being able to confirm the presence or absence of the translocation.


These items are provided solely for informational purposes and are not intended as a substitute for consultation with a medical professional. Patients with any specific questions about the items on this list or their individual situation should consult their physician.

How The List Was Created

The American Society of Dermatopathology (ASDP) is committed to improving the quality of lives by continually advancing the theory and practice of dermatopathology. In 2015, under the vision of the then Society President, Dr. Dirk Elston, the Appropriate Use Criteria (AUC) Task Force was created to help guide dermatopathologists and inform their clinical colleagues in their use of ancillary studies performed in dermatopathology in specific clinical scenarios. The overarching goal of producing AUC is high quality care, lowering costs, and ensuring efficient use of laboratory resources. The Task Force, which is now a committee, identified ancillary studies performed in dermatopathology encompassing four broad areas. These include: lymphoproliferative, melanocytic, soft tissue, and other, which includes entities that do not fit into one of the aforementioned groups. Using the methodology developed by RAND/ UCLA, which combines best scientific evidence with expert opinion, patient-centered guidelines (appropriateness ratings) have been created for ancillary studies used in dermatopathology. The AUC are used to develop these recommendations. The recommendations list was reviewed and approved by the ASDP Ethics Committee and Board of Directors.

Sources

Linos K, Kozel JA, Yadira Hurley M, Andea AA. Review of the medical literature and assessment of current utilization patterns regarding the use two common fluorescence in situ hybridization assays in the diagnosis of dermatofibrosarcomaprotuberans and clear cell sarcoma. J Cutan Pathol. 2018 Aug 28. [Epub ahead of print]

Vidal CI, Armbrect EA, Andea AA, et al. Appropriate Use Criteria in Dermatopathology: Initial Recommendations from the American Society of Dermatopathology. J Cutan Pathol. 2018 Aug;45(8):563-580 (full version) and J Am Acad Dermatol. 2018 Apr 21. [Epub ahead of print] (abbreviated version) [co-published].